Ilorasertib hydrochloride

A multi-kinase inhibitor

此产品仅用于科学研究，我们不为任何个人用途提供产品和服务

库存: 现货

可选规格

包装

价格

促销价

数量
1mg

￥875.00

700.00

- +
5mg

￥1737.00

1390.00

- +
10mg

￥2825.00

2260.00

- +
50mg

￥10250.00

8200.00

- +
100mg

￥17100.00

13680.00

- +
200mg

￥0.00

0.00

- +
500mg

￥0.00

0.00

- +

已选 0 种 0 瓶

金额: ￥0.00

首页收藏

Background

Ilorasertib is a multi-kinase inhibitor.¹ It inhibits Aurora C, VEGFR1, VEGFR2, FLT3, colony-stimulating factor 1 receptor (CSF1R), and Aurora B (IC₅₀s = 1, 1, 2, 1, 3, and 7 nM, respectively). It also inhibits PDGFRα, PDGFRβ, c-Kit, VEGFR3, and Aurora A (IC₅₀s = 11, 13, 20, 43, and 120 nM, respectively). Ilorasertib inhibits autophosphorylation of Aurora A, -B, and -C in HeLa cells with IC₅₀ values of 189, 13, and 13 nM, respectively. It inhibits proliferation of a variety of cancer cells, including MV4-11 acute myeloid leukemia (AML), SUP-B15 acute lymphocytic leukemia (ALL), and H1299 non-small cell lung cancer (NSCLC) cells (IC₅₀s = 0.3, 4, and 2 nM, respectively). It decreases histone H3 phosphorylation in blood-borne tumor cells in an engrafted mouse model of leukemia when administered at a dose of 25 mg/kg and reduces tumor growth in fibrosarcoma, pancreatic carcinoma, ALL, and multiple myeloma mouse xenograft models.

1.Glaser, K.B., Li, J., Marcotte, P.A., et al.Preclinical characterization of ABT-348, a kinase inhibitor targeting the aurora, vascular endothelial growth factor receptor/platelet-derived growth factor receptor, and Src kinase familiesJ. Pharmacol. Exp. Ther.343(3)617-627(2012)